$NOVO B If I remember, I had a split a few days ago. Now I have noticed that these are under sale with a loss of 10.60%? How can that be? In a split, the same shares are only divided or combined to equal parts of the value or am I wrong? In any case, it looks a bit strange, as if I had sold something at a loss.

Thank you very much and happy new year 🎆

edit: photo added of the sales.

IMPORTANT: I haven't sold a single share yet!

Podcast episode 68 "Buy High. Sell Low."

Subscribe to the podcast so that print dies.

00:00:00 Alphabet, Uber & Lyft

00:26:00 Novo Nordisk, Eli LIlly & Amgen

00:54:00 Quantum Computing & Quantum Corporation

01:02:15 Bitcoin & MicroStrategy

01:17:40 German Bitcoin experts

Spotify

https://open.spotify.com/episode/40XOPNBIC2zBjVtmVDSzMH?si=jj_ZclnGQfSfpRCUZEB2QQ

YouTube

https://youtu.be/rqzook0jqpU

Apple Podcast

https://podcasts.apple.com/de/podcast/folge-68-alphabet-microstrategy-novo-nordisk-uber-bitcoin/id1695869891?i=1000680672590

$GOOGL (-2,52 %)
$GOOG (-2,51 %)
$MSTR (+1,13 %)
$BTC (+0,02 %)
$UBER (-3,34 %)
$LYFT (-3,58 %)
$NOVO B (-3,97 %)
$NOVO B
$NVO (-3,45 %)
$AMGN (+1 %)$LLY (-2,51 %)
$AAPL (-4,74 %)
$SPOT (-1,84 %)
#podcast

Analyst updates, 02.12.24:

⬆️⬆️⬆️

- EXANE BNP upgrades NOVO NORDISK to Outperform. Target price DKK 930. $NOVO B

- HSBC upgrades LVMH to Buy. Target price EUR 727. $MC (-3,85 %)

- WARBURG RESEARCH raises target price for MTU from EUR 278 to EUR 297. Hold. $MTX (-8,74 %)

- GOLDMAN raises the price target for VISA from USD 324 to USD 347. Buy $V (-3,03 %)

- DEUTSCHE BANK RESEARCH upgrades BASF from Hold to Buy and raises price target from EUR 50 to EUR 55. $BAS (-3,2 %)

- DEUTSCHE BANK RESEARCH upgrades BURBERRY from Hold to Buy and raises target price from GBP 8.60 to GBP 11.80. $BRBY (-7,27 %)

- GOLDMAN raises the target price for AROUNDTOWN from EUR 2.90 to EUR 3.70. Buy. $AT1 (-4,32 %)

- GOLDMAN downgrades TOAST from Buy to Neutral and raises target price from USD 34 to USD 45. $TOST (-5,2 %)

- HSBC upgrades HERMES to Buy. Target price 2500 EUR. $RMS (-3,23 %)

- MORGAN STANLEY upgrades ZEBRA TECH to Equal-Weight. Target price 400 USD. $ZBRA (-2,83 %)

- JPMORGAN upgrades AIR LIQUIDE from Neutral to Overweight and raises target price from EUR 161 to EUR 195. $AI (+2,34 %)

- JPMORGAN raises target price for PUMA SE from EUR 44 to EUR 47. Neutral. $PUM (-5,04 %)

⬇️⬇️⬇️

- GOLDMAN lowers the price target for MASTERCARD from USD 563 to USD 557. Buy. $MA (-2,62 %)

- WARBURG RESEARCH lowers the price target for AIXTRON from EUR 26 to EUR 24. Buy. $AIXA (-7,63 %)

- METZLER lowers the price target for WACKER NEUSON from EUR 14.50 to EUR 14. Hold. $WAC (-7,7 %)

- DEUTSCHE BANK RESEARCH downgrades K+S from Hold to Sell and lowers target price from EUR 9.75 to EUR 9.50. $SDF (+0,84 %)

- BERENBERG lowers the price target for BP from GBP 4.70 to GBP 4.40. Hold. $BP. (-6,17 %)

- RBC downgrades IBERDROLA from Outperform to Sector-Perform. Target price EUR 14 $IBE (-1,33 %)

- RBC lowers the price target for RWE from EUR 52.50 to EUR 45.50. Outperform. $RWE (-2,38 %)

- JPMORGAN lowers the target price for ORSTED from DKK 460 to DKK 430. Neutral. $ORSTED (-2,52 %)

- JPMORGAN lowers the price target for ADIDAS from EUR 275 to EUR 266. Overweight. $ADS (-3,75 %)

- JPMORGAN lowers the price target for LVMH from EUR 685 to EUR 650. Neutral. $MC (-3,85 %)

- JPMORGAN lowers the price target for HUGO BOSS from EUR 43 to EUR 42. Neutral. $BOSS (-3,37 %)

Novo Nordisk Q3 2024 $NOVO B

Financial performance:

• Revenue: Net revenue increased by 23% to DKK 204,720 million in the first nine months of 2024 compared to DKK 166,398 million last year. In the third quarter of 2024, revenue amounted to DKK 71,311 million, an increase of 21% compared to Q3 2023.
• Net profit: Net profit increased by 18% to DKK 72,758 million in the first nine months of 2024, compared to DKK 61,720 million last year. In Q3 2024, net profit amounted to DKK 27,301 million, an increase of 21% compared to Q3 2023.
• EBITDA: EBITDA for the first nine months of 2024 was DKK 105,511 million, up 28% compared to DKK 82,229 million last year. In the third quarter, EBITDA increased by 22% to DKK 35,972 million.

Balance sheet overview:

• Total assets: As of September 30, 2024, total assets amounted to DKK 397,441 million compared to DKK 314,486 million at the end of 2023.
• Equity: Equity increased to DKK 120,522 million compared to DKK 106,561 million at the end of 2023.

Profit and loss account:

• Gross profit: Gross profit for the first nine months of 2024 increased by 23% to DKK 173,222 million. For Q3 2024, gross profit amounted to DKK 60,003 million, an increase of 22% compared to Q3 2023.
• Operating result: Operating profit for the first nine months of 2024 increased by 21% to DKK 91,602 million. In Q3 2024, it amounted to DKK 33,822 million, an increase of 26%.

Cash flow overview:

• Operating activities: Net cash flow from operating activities amounted to DKK 108,667 million, an increase of 9% against DKK 99,357 million in the previous year.
• Investment activities: Net cash flow for investments amounted to DKK -37,679 million compared to DKK -29,175 million in the previous year.
• Financing activities: Net cash flow for financing activities amounted to DKK -28,100 million, compared with DKK -53,042 million in the previous year.

Key figures and profitability metrics:

• Gross margin: The gross margin remained almost stable at 84.6% compared to 84.5% in the previous year.
• Operating margin: The operating margin was 44.7%, compared to 45.6% in the previous year.
• Net profit margin: The net profit margin decreased to 35.5%, compared to 37.1% in the previous year.

Segment information:

• Diabetes and Obesity Care: Revenue in the segment amounted to DKK 191,786 million for the first nine months of 2024, compared with DKK 153,806 million in the previous year.
• Rare diseases: Segment revenue amounted to DKK 12,934 million, compared to DKK 12,592 million in the previous year.

Competitive position:

• Market leadership: Novo Nordisk maintains its leadership position in the diabetes and obesity care market, particularly through growth in GLP-1 diabetes and obesity medicines.

Forecasts and management commentary:

• Outlook: The company expects continued growth driven by the diabetes and obesity segments, with a focus on international expansion and overcoming supply shortages.

Risks and opportunities:

• Risks: Include supply chain bottlenecks, regulatory changes and competition.
• Opportunities: Growth potential in obesity care, particularly due to strong demand for WegovyⓇ and expansion into international markets.

Summary of results:

Positive aspects:

• Strong sales increase of 23% in the first nine months of 2024.
• Net profit increase of 18%.
• Robust EBITDA growth of 28%.
• International expansion with sales growth of 21%.
• Successful market entry for WegovyⓇ in obesity care.

Negative aspects:

• Increased R&D costs by 56%.
• Supply bottlenecks affect product availability.
• Decline in net profit margin from 37.1 % to 35.5 %.
• Higher net cash flow requirement for investment activities.
• Challenges in maintaining operating margins.

The slimming injection Ozempic from Novo Nordisk has made it into its own South Park episode. Novo Nordisk shareholders like it. +448% in 5 years. Novo is the most valuable European share by market capitalization, ahead of LVMH, ASML and SAP. What percentage is the share up for you?

$NOVO B (-3,97 %)
$NOVO B
$ASML (-1 %)
$MC (-3,85 %)
$SAP (-2,94 %)
#novonordisk
#asml
#lvmh
#sap

#novonordisk
$NOVO B (-3,97 %)

NovoNordisk is researching a new appetite suppressant preparation, Amycretinshowed impressive results in a Phase 1 study.

According to CNBC, a daily pill of amycretin within three months leads to a weight loss of up to 13% within three months.

The results were presented at the annual meeting of the European Association for the Study of Diabetes (EASD). According to experts (an endocrinologist at Duke Health), the speed of weight loss with Amycretin outperforms other drugs, making the pill seem almost like a "miracle pill".

This data confirms earlier reports from Novo Nordisk and shows the potential of amylin-based drugs. Other Danish companies such as Zealand Pharma and Gubra are also working on similar programs. $NOVO B

https://www.deraktionaer.de/artikel/pharma-biotech/novo-nordisk-hoffnungstraeger-amycretin-fast-wie-eine-wunderpille-20365937.html

Novo Nordisk is a global leader in the healthcare industry specializing in the development, manufacturing and marketing of medicines for the treatment of diabetes, obesity, haemophilia and growth disorders. The company was founded in Denmark in 1923 and has grown over the decades to become one of the largest and most innovative pharmaceutical companies in the world.

Areas of activity:

1. Diabetes treatmentNovo Nordisk is the world's largest manufacturer of insulin and offers a wide range of insulin products.

2. ObesityNovo Nordisk has also made significant progress in the field of obesity treatment. Their drug Wegovy is used by some celebrities such as Elon Musk. Users are said to lose an average of 20% of their weight over 1.5 years.

3. Rare blood diseasesIn the field of rare diseases, especially hemophilia, Novo Nordisk offers products that contribute to blood clotting and help people with hemophilia to control bleeding.

4. Growth hormonesNovo Nordisk also produces growth hormones for patients with growth disorders.

Market position:

Novo Nordisk holds a dominant market share in the global diabetes market. With its broad product range and continuous innovation in the field of diabetes treatment, the company has consolidated a strong market position. Novo Nordisk operates globally and derives its revenues from a variety of markets, including North America, Europe and emerging markets such as China and Brazil.

Future prospects and growth opportunities

1. Growing diabetes marketThe prevalence of diabetes is increasing worldwide, mainly due to unhealthy lifestyles and an ageing population. This creates an increasing demand for diabetes treatments and positions Novo Nordisk well for future growth.

2. Expansion in obesity: The company has strong growth opportunities in obesity, particularly with the launch of Wegovy. As obesity becomes a major health problem worldwide, Novo Nordisk could benefit significantly from this expanding market.

3. Innovation in biopharmaceuticals: Novo Nordisk invests heavily in the research and development of new biopharmaceutical products. The focus on biologic drugs and innovative therapies offers significant growth opportunities in specialized niche markets.

4. Sustainability initiatives: Novo Nordisk has committed to carbon-neutral production by 2030. This could help the company to take a leading role in sustainable production, which is becoming increasingly important and could reduce costs in the long term.

Is swallowing the new injecting "insulin pill"?

At present, insulin has to be injected because it is a protein that is broken down and degraded in the gastrointestinal tract before it can enter the bloodstream. However, Novo Nordisk is working on a technology that could circumvent this problem.

- Oral administration of insulinNovo Nordisk is researching a capsule containing insulin that can be transported to the small intestine, where it is then absorbed directly into the blood. This would allow patients to take insulin without injections, which could significantly improve their quality of life.

- Microneedle technologyOne of the technologies Novo Nordisk is considering is the use of microneedles built into a small capsule. These capsules could contain a tiny needle that injects the insulin directly into the intestinal wall as soon as the capsule reaches the small intestine. This would protect the insulin from the digestive enzymes and allow it to enter the bloodstream efficiently.

- Research and developmentNovo Nordisk has already made some progress in the development of such technologies. For example, the company has already developed oral drugs such as semaglutide (sold under the name Rybelsus), which have proven successful. Semaglutide is a GLP-1 receptor agonist that was originally administered as an injection, but is now also available as a tablet, which represents a significant advance in diabetes treatment.

Challenges of the pill

- Stability of insulinInsulin must be stabilized in a form that can withstand the acidic conditions of the stomach and is only activated in the small intestine.

- Absorption and bioavailabilityIt must be ensured that a sufficient amount of insulin is absorbed by the body to effectively regulate blood glucose levels.

- Safety aspectsThe use of microneedles or other injecting mechanisms in a pill must be carefully evaluated for safety and tolerability.

Despite these challenges, the potential for oral insulin delivery is enormous. It could revolutionize the treatment of diabetes by eliminating the need for needles and injections, making therapy significantly more comfortable and less painful for patients.

What do you think of NovoNordisk and the future of the company?

I find it difficult to find the right time to get in. That's why I made partial purchases with a few transactions and have not regretted it to this day. I am not worried about the future and am holding my position.

Interesting video on the insulin pill:

https://youtu.be/SZYI_8Psv8w?si=XxDL3LX-P97pWkLP

$NOVO B

Novo Nordisk share - start of a correction at the all-time high. Increasing competitive pressure from Eli Lilly and Viking Therapeutics. Product pipeline and takeovers.

As always in web article format with pictures and an interactive live chart: Novo Nordisk Aktie

Hello everyone,

Novo Nordisk is the winner of the Aktienanalyse im März 2024. With over 21 percent of the votes you Novo Nordisk was chosen. The suggestion for this share came from the community in February.

Novo Nordisk share (ISIN: DK0062498333 / WKN: A3EU6F)

Novo Nordisk (WKN: A3EU6F / ISIN: DK0062498333) is a global leader in the healthcare sector specializing in diabetes care and Obesity Care. Diabetes and Obesity Care are responsible for 92.6% of Novo Nordisk's sales in 2023. Novo Nordisk is active in the research, development and manufacture of pharmaceutical products worldwide.

With the fight against chronic diseases such as diabetes, obesity and rare diseasesNovo Nordisk has established itself as a market leader in these areas. At the same time Novo Nordisk is Europe's largest and most valuable pharmaceutical group in terms of market capitalization.

The pharmaceutical group was founded in 1923 and is headquartered near Copenhagen in Bagsværd (Denmark).

CEO of Novo Nordisk is Lars Fruergaard Jørgensen. He took over the company in January 2017, utilizing his many years of experience in the pharmaceutical industry. Jørgensento further establish Novo Nordisk as a leading company in the healthcare industry.

Novo Nordisk share real time price chart

Novo Nordisk is close to its all-time high and continues the strong growth since 7 years.

Live Chart ist hier zu finden

Novo Nordisk latest news and announcements

The hype surrounding the weight loss injection Wegovy with the active ingredient semaglutide began in Hollywood, with Kim Kardashian and Elon Musk using the product to lose weight. Sales led to ever higher all-time highs. Ozempic for type 2 diabetics also contains the active ingredient semuglutide. Driven by the two weight loss drugs Ozempic and Wegovy, operating profit rose by over 44 percent in 2023, making Novo Nordisk the most valuable company in Europe.

Awiqli shortly before EU approval

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion on the approval of Awiqli for the treatment of adults with diabetes, referring to the results of the ONWARDS clinical trial program (Phase 3a study). With Awiqli, it is possible to reduce the number of injections required from 7 to just 1 per week and thus significantly improve the treatment methodology. The drug has not yet received final approval, as the European Commission has not yet given its consent, although it generally follows the EMA's recommendation, which is already available.

Zepbound from Eli Lilly

The competition between Novo Nordisk and Eli Lilly is currently at its peak. For the first time since the launch of Zepbound in December 2023, Eli Lilly has recorded more prescriptions in the USA than Novo Nordisk, which has been on the market for two years.

VK2735 from Viking Therapeutics

The Californian biotech company Viking Therapeutics is currently testing its new drug VK2735 in a phase 2 trial, which is designed to burn body fat five times faster than Wegovy. Depending on the dose, 140 test subjects were able to lose between 9 and 15 percent of their body weight in 13 weeks. Wegovy promises a weight loss of 15 percent in 18 months.

New miracle drug Amycretin

Amycretin is the new hope from Novo Nordisk. The bestseller Wegovy (semaglutide), which has been approved since 2022, Zepbound from Eli Lilly and VK2735 from Viking Therapeutics are drugs that have to be injected. Amycretin is a pill that is convincing in the Phase I trial. After 12 weeks, the study participants were able to lose 13.2 percent of their body weight, compared to 6 percent for Wegovy over the same period.

A pill with twice the effectiveness, without the disadvantages of the previous obesity drug Wegovy, could revolutionize the weight loss industry and would be the drug of choice. A pill would be more acceptable than weekly injections over a period of many months. It will still take some time before approval is granted.

A few hours ago Reuters the success of a Viking Therapeutics study on the new weight loss pill. The Viking Therapeutics share price rose by 10 percent following the announcement. Here, too, it is clear that the market is highly competitive and that the competition is not sleeping.

In 2023, Novo Nordisk generated sales equivalent to around 28.8 billion euros in the diabetes and obesity care segment. Analysts from JPMorgan estimate the GLP-1 market (diabetes and obesity) for weight loss products at 100 billion dollars by 2030 and thus expect strong growth in the industry.

Cardior Pharmaceuticals acquisition

The biotech start-up Cardior Pharmaceuticals Ltd.announced on Monday in einer gemeinsamen Meldung the takeover by Novo Nordisk for 1.025 billion euros.

Cardior is a spin-off of the Hannover Medical School (MHH). The therapy for heart disease and heart failure developed by the start-up is currently in a Phase II study. Novo Nordisk is to accelerate development, is the ideal partner for Cardior and at the same time strengthens its own cardiovascular pipeline.

With the development new products and the expansion of its own portfolio through acquisitionsNovo Nordisk confirms its growth growth plans.

Facts, figures and data

Annual report 2023 and outlook 2024

On 31.01.2024 Novo Nordisk publishes the Annual Report 2023. In the annual review, Novo Nordisk confirms its growth trajectory and provides an outlook for 2024.

The most important figures summarized:

• Sales grows by 31 percent to 232.3 billion Danish kroner in 2023
• Operating profit increases by 37 percent to 102.6 billion kroner
• Net profit increases by 51 percent to 83.7 billion kroner
• The dividend increases to 9.40 Danish kroner per share. Dividends are paid out in March and August.

The outlook remains strongthe growth rates are estimated to be more moderate due to increasing competition from Eli Lilly. Sales are expected to increase by 18 to 26 percent and operating profit by 21 to 29 percent.

Share buyback

Novo Nordisk has been for over 20 years regularly share buybacks for 20 years. This strengthens the share price on the one hand and increases profit growth on the other.

A share buyback program is also planned for 2024. share buyback program in the amount of 20 billion euros has been announced.

Novo Nordisk's profit flow

The Profit flow 2023 presents the quarterly figures and illustrates the company's specialization in the Diabetes and Obesity Care segment with over 92 percent of sales.

Fair value

Based on the reported business figures for 2023, the Aktienfinder.net analysis tool gives a calculated fair share price of DKK 456. The share price therefore appears to have already priced in many positive developments and would therefore be overvalued. This is also confirmed by the current P/E ratio of just over 49.

31 analyst opinions on the Novo Nordisk share

The current sentiment of the analysts as of 22.03.2024 on Consorsbank / FactSets is as follows. Out of a total of 31 analysts:

• 17 buy
• 3 overweight
• 8 hold
• 0 underweight
• 3 sell

The price potential for the year is currently estimated at DKK 955 at 7,01 % seen. The average analyst opinion is hold to buy.

Novo Nordisk is at an all-time high and has already risen 28% YTD since January 2024.

Novo Nordisk share chart analysis

Big Picture (20 years)

In the Big Picture (20-year view, 1 candle = 3 months) Novo Nordisk is in a 20-year upward trend. upward trend. The last real correction was in year 2016. At that time, the share price fell by 50 percent within one year. The reason was strong competitive pressure from Eli Lilly and Sanofi for insulin-products, as well as price pressure from health insurers in the USA.

Growth forecasts, sales growth, operating profit and the outlook were lowered by management at the time.

With trial successes and the approval of Ozempic (Semaglutide), Novo Nordisk made a comeback one year later. comeback. With Ozempic and Wegovy Novo Nordisk was able to increase its sales by 700 percent within 7 years.

The big picture shows the upward trend remains activealthough the indicators are strongly overboughtbut so far signaling no trend reversal.

200% Wegovy uptrend

The 2-year upward trend in the medium-term chart with one candle = 1 week shows the first signs of overheating and stagnating momentum. The trend is still active, the price is even breaking out of the trend channel to the upside, but is beginning to weaken and falls back into the trend channel. Like the big picture, the RSI index shows clear signs of overheating and overbought situation and is starting to correct slightly. correction to fall with the correction. The MACD is stagnating at a very high level and indicates an imminent trend reversal.

If the correction in the medium-term chart is confirmed by mid-April, an extension of the correction must be expected. extension of the correction within the upward trend must be expected. Possible targets:

• Correction target 1 at DKK 808 (approx. EUR 108) at the February low
• Correction target 2 at DKK 740 (approx. EUR 100) at the October high and approx. Fibonacci retracement 61.8 percent

Indicators (RSI, MACD)

The indicators MACD and RSI are already in correction mode on the daily chart. They point to an overbought situation situation. The daily chart shows a double top which also points to a correction. If the correction does not end within a few days, the indicators in the weekly chart will also switch to correction mode.

Overarching the upward upward trend. As long as no negative news fundamentally changes the valuation of the share, the correction targets are possible entry and subsequent purchase prices, provided that one is convinced of the company.

Conclusion Novo Nordisk share analysis 2024

Environment and news

With increasing competitive pressure from Eli Lilly, the diabetes and obesity market no longer belongs to Novo Nordisk alone. This will change the environment for Novo Nordisk more demanding. In the long term, things continue to look good. There are enough products in the pipeline. Novo Nordisk is strengthening its product portfolio with takeovers and acquisitions. Overall, things are looking good for the industry. The market is expected to grow and reach a value of 100 billion dollars by 2030. However, the share currently appears to be highly valued and to have priced in many positive scenarios.

Analysts' sentiment

In view of the strong rise in the share price of 700% in the last 7 years and an increase of almost 30% in the first 3 months of the year, the analysts' forecast target is more cautious. more cautious more cautious. With an average price target of DKK 955, the price potential for the year is currently 7.01 percent. The average analyst opinion is hold to buy.

Novo Nordisk share chart analysis

The chart analysis signals the first signs of weakness in the short-term chart and indicates the beginning of a correction correction within the upward trend trend. In the medium-term chart, the price is at the upper limit of the upward trend and the indicators are overbought.

Overarching the upward trend remains activecorrections represent an entry opportunity.

Outlook

In the long term the diabetes and obesity market looks good. According to JPMorgan, the GLP-1 market is expected to grow to over 100 billion dollars. Novo Nordisk has a good pipeline with promising products and is continuing to grow.

In the short term the share is overbought and is in a correction at its all-time high. The competition is reporting its own successes with comparable products. It is becoming increasingly difficult for Novo Nordisk to maintain its exponential growth, so a correction within the positive long-term trend must be expected. With the information available today, corrections offer an attractive opportunity to enter the share.

As always: No investment advice and no recommendation to act. Purely an informative article.

I appreciate every follow ❤️

$NOVO B
$VKTX (-3,98 %)
$SAN (-2,08 %)
$LLY (-2,51 %)
$NOVO B (-3,97 %)
$NOVO B

All good things come in threes. November was the second-best November since I started investing. December was also the second best December. And what follows in January? The second-best January for me since August 2013, of course.

January saw a performance of +6,1%. Only January 2015 was even better with +6.7%.

Compared to my benchmark (MSCI World), this was an extremely good start to 2024. The MSCI World had "only" gained 3% in January.

On the winning side were once again the usual suspects in January. The strongest position was once again NVIDIA $NVDA (-3,85 %)
with a gain of over €3,000.

The following positions were also occupied by the usual suspects with Palo Alto Networks $PANW (-2,67 %) ASML $ASML (-1 %) Microsoft $MSFT (-1,34 %) and Crowdstrike $CRWD (-3,69 %)

On the losers' side, there is also little new: In addition to Encavis $ECV and Block $SQ (-8,69 %) the main loser here is of course China with my China ETF $MCHS (-4,99 %)

However, the China ETF only accounts for ~2% of my portfolio in total. That's why I'm continuing to look at it for the time being. However, I have not made any additional purchases via a savings plan since January. For me, this is a classic hold position at the moment.

In January, I invested a total of ~1.300€ in total. As already mentioned in my 2023 portfolio statement, I will have to reduce my investments in 2024 for the time being, at least in the first half of the year. The reason for this is some private expenses.

As I also had to use some of my cash reserves for this, I only added ~€500 net to my assets.

Focusing purely on this key figure, January was one of the worst months in years - but monthly investments should pick up again in the second half of 2024 at the latest.

Purchases & sales:

• As mentioned, I bought in January for ~1.300€
• As always, my savings plans were executed:
• Blue ChipsNovo Nordisk $NOVO B LVMH $MC (-3,85 %) Apple $AAPL (-4,74 %) Home Depot $HD (-1,79 %) Microsoft $MSFT (-1,34 %) Nike $NKE (-5,63 %) Starbucks $SBUX (-5,42 %) Texas Instruments $TXN (-4,41 %) Stryker $SYK (-2,3 %)
  
• GrowthCrowdstrike $CRWD (-3,69 %) MercadoLibre $MELI (-3,12 %)
  
• ETFsMSCI World $XDWD Nikkei 225 $XDJP and the WisdomTree Global Quality Dividend Growth $GGRP
• CryptoBitcoin $BTC and Ethereum $ETH
• Sales there were none in January

In total, my portfolio now stands at ~268.000€. This corresponds to an absolute increase of ~€16,000 in January. ~15.000€ of this comes from price gains, ~140€ from dividends / interest and ~500€ from additional investments.

In absolute figures, January was the best month ever with the above-mentioned ~€15,000 price gains. I normally have to go to work for ~4 months to earn this money!

Dividend:

• The dividends in January were +37% above the previous year at ~€115
• Nike had a very unfavorable dividend policy last year and this year. The fourth dividend payment unfortunately only came in January. As a result, Nike paid out 3x in 2023 and will pay out 5x this year. In order to achieve better comparability, I recorded the dividend in December in Portfolio Performance as usual. If I had recorded the dividend in January, the growth would even be +50%
• The announcement of a dividend at Meta is also exciting $META (-5,03 %)
  
• The big tech companies are generating endless cash flows, so it is only a matter of time before this money has to flow to shareholders. That leaves only Amazon $AMZN (-6,41 %) and Alphabet $GOOG (-2,51 %) as Microsoft and Apple have been paying dividends for a long time now
• I am curious to see whether these two companies will soon follow the Meta example and become dividend payers

With the continued very positive outlook for Big Tech, I am optimistic that the target for this year (€300,000 by the end of 2024) should definitely be achievable. Even if I have to significantly reduce my investments compared to the last few years.

What are your favorites for this year?

After 2023 clearly belonged to NVIDIA, Meta, Novo Nordisk and Eli Lilly, I wonder who the big winners will be in 2024?

If you look at January, these stocks are once again at the top.

In my view, however, this cannot continue for the whole year and there will certainly be other winners.

Where do you see exciting long-term opportunities for the rest of the year?

#dividends
#dividende
#rückblick
#depotupdate
#aktie
#stocks
#etfs
#crypto
#personalstrategy
#tech

NEW NORDISK IS IT TIME TO BUY? ACTION ANALYSIS and BUSINESS MODEL. #novonordisk
#ozempic

https://youtu.be/7mhoe1KFtD4
$NOVO B (-3,97 %)
$NOVO B